Chugai Pharmaceutica (CHGCF) 26.0000 $CHGCF
Global Gouty Arthritis (Gout) therapeutics Pipeline Review 2014
M2 - Tue Apr 29, 8:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/34c3mc/gouty_arthritis) has announced the addition of the "Gouty Arthritis (Gout) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Gouty Arthritis (Gout), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gouty Arthritis (Gout) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Gouty Arthritis (Gout) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Gouty Arthritis (Gout) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Gouty Arthritis (Gout) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Gouty Arthritis (Gout) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - UMeWorld Limited - AstraZeneca PLC - Teijin Pharma Limited - Novartis AG - Chugai Pharmaceutical Co., Ltd. - Kissei Pharmaceutical Co., Ltd. - Addex Therapeutics - BioCryst Pharmaceuticals, Inc. - Nippon Chemiphar Co., Ltd. - JW Pharmaceutical Corporation - LG Life Sciences, Ltd. - Wellstat Therapeutics Corporation - Opsona Therapeutics Ltd. - PLx Pharma Inc. - Polaris Group - Selvita S.A - Delenex Therapeutics AG - Immune Response BioPharma, Inc. - TWi Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/34..._arthritis
Global Kidney Disease Therapeutics Pipeline Review 2014 - Analysis of 22 Companies & 32 Drug Profiles
M2 - Mon Apr 28, 5:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ls4c8m/kidney_disease) has announced the addition of the "Kidney Disease - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Kidney Disease - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Kidney Disease and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Kidney Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Kidney Disease pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Sanofi - Nektar Therapeutics - Chugai Pharmaceutical Co., Ltd. - LEO Pharma A/S - Teva Pharmaceutical Industries Limited - Zydus Cadila Healthcare Limited - Gentium S.p.A. - Celldex Therapeutics, Inc. - Osteologix Holdings Plc. - Ahn-Gook Pharmaceutical Co., Ltd. - DiaMedica Inc. - Upsher-Smith Laboratories, Inc. - TetraLogic Pharmaceuticals - ChemoCentryx, Inc. - Anexon, Inc. - Otsuka Holdings Co., Ltd. - BIOPROJET SCR - Advicenne Pharma - ZS Pharma, Inc. - G1 Therapeutics, Inc. - AbbVie Inc. Drug Profiles - ADV-7809 - benazepril hydrochloride - ADV-7103 - tolvaptan - methylprednisolone - ZS-9 - AGNPN-803 - hydrocodone bitartrate ER - LEO-27847 - DM-199 - tiprolisant - CCX-872 - RG-7641 - CDX-1189 - CU-NP - Necrostatin Program - Oligotide - NKTR-228 - CCR2 Antagonist - CH-5451098 - SkQR-1 - TNT-009 - SLR-080811 Derivative - AVE-0991 - NBS-101 - Prod-1 - messenger RNA Therapeutics Program - AHRO-200 - CDK-4/6 Inhibitors As Renal Protectants - A77-Based Monobody For more information visit http://www.researchandmarkets.com/research/ls...ey_disease
Global Benign Prostatic Hyperplasia Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 4:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f348jl/benign_prostatic) has announced the addition of the "Global Benign Prostatic Hyperplasia Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Benign Prostatic Hyperplasia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Benign Prostatic Hyperplasia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Eli Lilly and Company - Euroscreen S.A. - Aphios Corporation - Astellas Pharma Inc. - Chong Kun Dang Pharmaceutical Corp. - Chugai Pharmaceutical Co., Ltd. - SK Chemicals Co., Ltd. - Addex Therapeutics - AEterna Zentaris Inc. - IntelGenx Corp. - Kaken Pharmaceutical Co., Ltd. - Karo Bio AB - Nymox Pharmaceutical Corporation - Quest PharmaTech Inc. - Sophiris Bio, Inc. - AndroScience Corporation - NovaLead Pharma Pvt. Ltd. - AmVac AG - KAEL-GemVax Co., Ltd. - Ausio Pharmaceuticals, LLC - Hanmi Pharmaceuticals, Co. Ltd. - SOM Biotech SL - Curadis GmbH - Balonco GMBH Drug Profiles - tadalafil - NX-1207 - topsalysin - MCS-2 - ozarelix - teverelix - AUS-131 - udenafil - AMV-110 - ASP-4901 - AMV-100 - ASP-0306 - ASP-6432 - CKD-902 - ADX-68692 - Sperol - tertomotide - ASC-JM.X2 - VLDM-01 - ESN-364 - SL-052 - Estrogen Receptor Program - S-40542 - NCE-403 - SOM-2391 - (tamsulosin dutasteride) - CH-5036249 - L1AD3 - Kisspeptin Peptide Antagonists - CR-1493 - SOM-2393 - Small Molecule to Inhibit Steroidal 5-Alpha Reductase for Benign Prostatic Hyperplasia - INT-0031 For more information visit http://www.researchandmarkets.com/research/f3..._prostatic
Chugai Pharma USA Announces Appointment of Chief Medical Officer
PR Newswire - Fri Apr 25, 1:00AM CDT
Chugai Pharma USA, LLC (CPUSA), Berkeley Heights, NJ a wholly owned subsidiary of Chugai Pharmaceutical Co., Ltd. (Chugai) Tokyo, Japan, member of the Roche Group, appoints Athos Gianella-Borradori, M.D. as Chief Medical Officer of CPUSA.
Former Roche Pharmaceuticals CEO Joins Mesoblast Board of Directors
GlobeNewswire - Wed Mar 05, 6:24PM CST
Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced that William M. Burns, former Chief Executive Officer of Roche Pharmaceuticals, has been appointed a non-executive Director of the Mesoblast Board, effective immediately.
Global 3D Flat Panel TV Market 2014-2018: Several Videogame Makers Investing Heavily in Making 3D Video Games
M2 - Thu Feb 13, 6:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/bjrqxw/global_3d_flat) has announced the addition of the "Global 3D Flat Panel TV Market 2014-2018" report to their offering. The analysts forecast the Global 3D Flat Panel TV market to grow at a CAGR of 15.4 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increase in 3D content broadcasts. The Global 3D Flat Panel TV market has also been witnessing the emergence of 4K resolution technology. However, the health risk associated with 3D technology could pose a challenge to the growth of this market. Key vendors dominating this space are LG Electronics Inc., Samsung Electronics Co. Ltd., and Sony Corp. Other vendors mentioned in the report are Panasonic Corp., Koninklijke Philips N.V., Sharp Corp., and Toshiba Corp. Commenting on the report, an analyst from the team said: The increasing popularity of 3D gaming among consumers is driving the Global 3D Flat Panel TV market. 3D gaming is an immersive experience that provides a real world experience to its users. Several videogame makers such as Sony Computer Entertainment Inc., Nintendo Co. Ltd., Electronic Arts Inc., Capcom Co. Ltd., Take-Two Interactive Software Inc., and Warner Bros. Interactive Entertainment Inc. are investing heavily in making 3D video games. This increasing popularity of 3D games has encouraged the vendors to manufacture and upgrade 3D TVs to support 3D gaming. According to the report, 3D technology is being used in the Entertainment sector such as 3D films, video games, gaming consoles, and 3D TVs. Blockbuster movies like Avatar not only increased the public awareness of 3D media but also increased the popularity of 3D films across the world. For more information visit http://www.researchandmarkets.com/research/bj...al_3d_flat About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Research Report: Hyperuricemia - Pipeline Review, H2 2013
M2 - Thu Dec 12, 2:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/3dtg38/hyperuricemia) has announced the addition of the "Hyperuricemia - Pipeline Review, H2 2013" report to their offering. 'Hyperuricemia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hyperuricemia, complete with latest updates, and special features on late-stage and discontinued projects. Scope - A snapshot of the global therapeutic scenario for Hyperuricemia. - A review of the Hyperuricemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hyperuricemia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Hyperuricemia. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Hyperuricemia pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned AstraZeneca PLC Teijin Pharma Limited Chugai Pharmaceutical Co. Ltd Kissei Pharmaceutical Co., Ltd. Nippon Chemiphar Co., Ltd. Polaris Group For more information visit http://www.researchandmarkets.com/research/3d...eruricemia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Helsinn and Chugai Pharma Marketing Enter into Agreement for Rights of Anamorelin, Currently in Development for Treatment of Anorexia-Cachexia Syndrome Related to Non-small Cell Lung Cancer in top EU Markets
PR Newswire - Mon Nov 11, 9:00PM CST
Swiss Pharma Group Helsinn seals an alliance with Japanese company Chugai by granting exclusive distribution & licensing rights to commercialize its innovative phase III ghrelin receptor agonist in Germany, France, Benelux, UK and Ireland
Hemophilia - Pipeline Review, H2 2013
M2 - Tue Sep 10, 3:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rvbm6c/hemophilia) has announced the addition of the "Hemophilia - Pipeline Review, H2 2013" report to their offering. 'Hemophilia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hemophilia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hemophilia. Scope - A snapshot of the global therapeutic scenario for Hemophilia. - A review of the Hemophilia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hemophilia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Baxter International Inc. Biogen Idec Inc. AstraZeneca PLC Nektar Therapeutics Cangene Corporation Lentigen Corporation Sangamo BioSciences, Inc. Pharming Group N.V. Novo Nordisk A/S BioMarin Pharmaceutical Inc. Chugai Pharmaceutical Co. Ltd Dong-A Pharmaceutical Co., Ltd. GTC Biotherapeutics, Inc. Octapharma AG Pain Therapeutics, Inc. Pfizer Inc. Bayer AG Living Cell Technologies Limited PROLOR Biotech, Inc. ReGenX Biosciences, LLC Alnylam Pharmaceuticals, Inc CSL Limited and many more... For more information visit http://www.researchandmarkets.com/research/rvbm6c/hemophilia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Kidney Disease - Pipeline Review, H2 2013
M2 - Thu Sep 05, 8:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zv6w3f/kidney_disease) has announced the addition of the "Kidney Disease - Pipeline Review, H2 2013" report to their offering. 'Kidney Disease - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Kidney Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Kidney Disease. Scope - A snapshot of the global therapeutic scenario for Kidney Disease. - A review of the Kidney Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Kidney Disease pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Genzyme Corporation Baxter International Inc. AstraZeneca PLC Eli Lilly and Company Quark Pharmaceuticals, Inc. Merck & Co., Inc. BioLineRx, Ltd. FibroGen, Inc. Novartis AG Chugai Pharmaceutical Co. Ltd Kureha Corporation LEO Pharma A/S Pfizer Inc. Zydus Cadila Healthcare Limited Hadasit Medical Research Services & Development Ltd NephroGenex, Inc. Cyclacel Pharmaceuticals Inc. OPKO Health, Inc. Evotec Aktiengesellschaft GENTIUM S.p.A. Celldex Therapeutics, Inc. Osteologix, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/zv...ey_disease About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Osteoarthritis - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nkkfb7/osteoarthritis) has announced the addition of the "Osteoarthritis - Pipeline Review, H2 2013" report to their offering. 'Osteoarthritis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Osteoarthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Osteoarthritis. Scope - A snapshot of the global therapeutic scenario for Osteoarthritis. - A review of the Osteoarthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Osteoarthritis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Johnson & Johnson Osiris Therapeutics, Inc. Seikagaku Corporation Sanofi-Aventis Ablynx TiGenix NV Novartis AG Astellas Pharma Inc. Chong Kun Dang Pharmaceutical Chugai Pharmaceutical Co. Ltd Pfizer Inc. Menarini Group Merck KGaA Bone Medical Limited Addex Pharmaceuticals Can-Fite BioPharma Ltd. Medivir AB Mesoblast Ltd Calzada Limited NicOx SA and many more... For more information visit http://www.researchandmarkets.com/research/nk...oarthritis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Eczema - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7twqxc/eczema_pipeline) has announced the addition of the "Eczema - Pipeline Review, H2 2013" report to their offering. 'Eczema - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Eczema, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Eczema. Scope - A snapshot of the global therapeutic scenario for Eczema. - A review of the Eczema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Eczema pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company GlaxoSmithKline plc Daiichi Sankyo Company, Ltd Merck & Co., Inc. Taisho Pharmaceutical Co., Ltd. Novartis AG Chugai Pharmaceutical Co. Ltd Dr. Reddy's Laboratories Limited Eisai Co., Ltd. Galderma S.A. LEO Pharma A/S Mitsubishi Tanabe Pharma Corporation Nippon Shinyaku Co., Ltd. Sun Pharmaceutical Industries Limited Sandoz Inc. Bayer AG AlbireoPharma Almirall, S.A. NicOx SA Regeneron Pharmaceuticals, Inc. Array BioPharma Inc. ProMetic Life Sciences Inc. and many more... For more information visit http://www.researchandmarkets.com/research/7t...a_pipeline About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Hepatitis C - Pipeline Review, H2 2013
M2 - Mon Sep 02, 8:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wq4dm8/hepatitis_c) has announced the addition of the "Hepatitis C - Pipeline Review, H2 2013" report to their offering. 'Hepatitis C - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hepatitis C, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatitis C. Scope - A snapshot of the global therapeutic scenario for Hepatitis C. - A review of the Hepatitis C products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hepatitis C pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Johnson & Johnson Boehringer Ingelheim GmbH F. Hoffmann-La Roche Ltd. United Therapeutics Corporation Medgenics Inc. Valeant Pharmaceuticals International GlaxoSmithKline plc Tekmira Pharmaceuticals Corp. Inovio Biomedical Corporation Idenix Pharmaceuticals, Inc. Gilead Sciences, Inc. Biotest AG Merck & Co., Inc. Lentigen Corporation BioLineRx, Ltd. Biotron Limited Novartis AG Isotechnika Pharma Inc. Achillion Pharmaceuticals, Inc. Chugai Pharmaceutical Co. Ltd and many more.... For more information visit http://www.researchandmarkets.com/research/wq...epatitis_c About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Research and Markets: Medical Chemicals (Global) Companies 2013 - Individual Assessment of the Top 100 Companies Featuring Chugai, Astra Zeneca and Boirin
Business Wire - Fri Jul 26, 11:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6qxgsf/medical_chemicals) has announced the addition of the "Medical Chemicals (Global)" report to their offering.
Medical Chemicals (Global) Companies 2013 - Individual Assessment of the Top 100 Companies Featuring Chugai, Astra Zeneca and Boirin
M2 - Fri Jul 26, 9:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8wzmsj/medical_chemicals) has announced the addition of the "Medical Chemicals (Global)" report to their offering. Plimsoll Publishing's Medical Chemicals (Global) Analysis provides a detailed overview of the Medical Chemicals (Global) market and delivers a comprehensive individual analysis on the top 100 companies, including CHUGAI PHARMACEUTICAL CO., LTD., ASTRAZENECA PTY LIMITED and BOIRON SA. This report includes a wealth of information on the financial trends over the past four years. Plimsoll Publishing's latest Medical Chemicals (Global) analysis is ideal for anyone wanting to: - See the market leaders - Identify companies heading for failure - Seek out the most attractive acquisition - Analyse industry trends - Benchmark their own financial performance Using Plimsoll's exclusive methodology, a quick glance of this Medical Chemicals (Global) report will tell you that 6 companies have a declining Plimsoll financial rating, while 15 have shown good sales growth. Each of the largest 100 companies is meticulously scrutinised in a one-page individual assessment and is analysed using the most up-to-date and current financial data. Every business is examined on the following features: - The Plimsoll Chart: A graphical assessment of a company's financial performance - An independent financial valuation - Four year assessment of the profit/loss and balance sheet - A written summary highlighting key performance issues Subsequently, you will receive a thorough market analysis highlighting the latest changes in the Medical Chemicals (Global) market. This section includes: - Best Trading Partners - Sales Growth Analysis - Profit Analysis - Market Size - Rankings For more information visit http://www.researchandmarkets.com/research/8w..._chemicals
Analysis of Nippon Kayaku 2013
M2 - Wed Apr 17, 4:11AM CDT
Research and Markets has announced the addition of the "Analysis of Nippon Kayaku" company profile to their offering. Aruvian Research presents Analysis of Nippon Kayaku. A complete and comprehensive analysis of Nippon Kayaku includes an overview of the industry the company operates in and then moves on to analyzing the company itself. Nippon Kayaku Co. Ltd. is a diversified chemical producer. The Company manufactures pharmaceuticals, dyestuffs, agrochemicals, explosives and synthetic resins. The Company also produces airbag inflators. It's product line include epoxy resins, UV-curing type resins, optical functional films, colors for inkjet printers, catalysts, pharmaceuticals, pharmaceutical API and intermediates, diagnostics, airbag inflators, micro gas generators for seatbelt pretensioners, squibs, agrochemicals and dyes, among others. The company also offers real estate leasing and contract manufacturing to pharmaceutical companies. Nippon Kayaku conducts its business through four reportable segments
Analysis of Chugai Pharmaceutical - In-depth Company Analysis 2013
M2 - Tue Apr 16, 9:53AM CDT
Research and Markets has announced the addition of the "Analysis of Chugai Pharmaceutical" company profile to their offering. Aruvian Research presents Analysis of Chugai Pharmaceutical. A complete and comprehensive analysis of Chugai Pharmaceutical includes an overview of the industry the company operates in and then moves on to analyzing the company itself. Chugai Pharmaceutical Co. Ltd. is a Japan-based pharmaceutical company. The Company operates in two business segments. The Domestic segment is engaged in the sale of pharmaceutical products manufactured by the Company through its nationwide appointed stores. This segment is also involved in the research, development, transportation and storage of pharmaceutical products, as well as the provision of literature research services for pharmaceutical information. The Overseas segment is engaged in the sale of its pharmaceutical products in overseas markets, such as Germany, the United Kingdom, France, Taiwan, China Mainland, Korea and the United States. T
Chugai and Debiopharm Group Announce an Exclusive License Agreement for Anti-Cancer Agent, FF284 (Debio 1347)
PR Newswire - Tue Jan 08, 12:00AM CST
Chugai Pharmaceutical Co., Ltd. ("Chugai"
and Debiopharm GroupTM ("Debiopharm" announced today that on December 17, 2012, they entered into a licensing agreement regarding FF284 (called Debio 1347 by Debiopharm) discovered by Chugai and which is about to start clinical development in oncology.
Global Gouty Arthritis (Gout) therapeutics Pipeline Review 2014
M2 - Tue Apr 29, 8:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/34c3mc/gouty_arthritis) has announced the addition of the "Gouty Arthritis (Gout) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Gouty Arthritis (Gout), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gouty Arthritis (Gout) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Gouty Arthritis (Gout) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Gouty Arthritis (Gout) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Gouty Arthritis (Gout) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Gouty Arthritis (Gout) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - UMeWorld Limited - AstraZeneca PLC - Teijin Pharma Limited - Novartis AG - Chugai Pharmaceutical Co., Ltd. - Kissei Pharmaceutical Co., Ltd. - Addex Therapeutics - BioCryst Pharmaceuticals, Inc. - Nippon Chemiphar Co., Ltd. - JW Pharmaceutical Corporation - LG Life Sciences, Ltd. - Wellstat Therapeutics Corporation - Opsona Therapeutics Ltd. - PLx Pharma Inc. - Polaris Group - Selvita S.A - Delenex Therapeutics AG - Immune Response BioPharma, Inc. - TWi Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/34..._arthritis
Global Kidney Disease Therapeutics Pipeline Review 2014 - Analysis of 22 Companies & 32 Drug Profiles
M2 - Mon Apr 28, 5:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ls4c8m/kidney_disease) has announced the addition of the "Kidney Disease - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Kidney Disease - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Kidney Disease and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Kidney Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Kidney Disease pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Sanofi - Nektar Therapeutics - Chugai Pharmaceutical Co., Ltd. - LEO Pharma A/S - Teva Pharmaceutical Industries Limited - Zydus Cadila Healthcare Limited - Gentium S.p.A. - Celldex Therapeutics, Inc. - Osteologix Holdings Plc. - Ahn-Gook Pharmaceutical Co., Ltd. - DiaMedica Inc. - Upsher-Smith Laboratories, Inc. - TetraLogic Pharmaceuticals - ChemoCentryx, Inc. - Anexon, Inc. - Otsuka Holdings Co., Ltd. - BIOPROJET SCR - Advicenne Pharma - ZS Pharma, Inc. - G1 Therapeutics, Inc. - AbbVie Inc. Drug Profiles - ADV-7809 - benazepril hydrochloride - ADV-7103 - tolvaptan - methylprednisolone - ZS-9 - AGNPN-803 - hydrocodone bitartrate ER - LEO-27847 - DM-199 - tiprolisant - CCX-872 - RG-7641 - CDX-1189 - CU-NP - Necrostatin Program - Oligotide - NKTR-228 - CCR2 Antagonist - CH-5451098 - SkQR-1 - TNT-009 - SLR-080811 Derivative - AVE-0991 - NBS-101 - Prod-1 - messenger RNA Therapeutics Program - AHRO-200 - CDK-4/6 Inhibitors As Renal Protectants - A77-Based Monobody For more information visit http://www.researchandmarkets.com/research/ls...ey_disease
Global Benign Prostatic Hyperplasia Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 4:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f348jl/benign_prostatic) has announced the addition of the "Global Benign Prostatic Hyperplasia Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Benign Prostatic Hyperplasia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Benign Prostatic Hyperplasia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Eli Lilly and Company - Euroscreen S.A. - Aphios Corporation - Astellas Pharma Inc. - Chong Kun Dang Pharmaceutical Corp. - Chugai Pharmaceutical Co., Ltd. - SK Chemicals Co., Ltd. - Addex Therapeutics - AEterna Zentaris Inc. - IntelGenx Corp. - Kaken Pharmaceutical Co., Ltd. - Karo Bio AB - Nymox Pharmaceutical Corporation - Quest PharmaTech Inc. - Sophiris Bio, Inc. - AndroScience Corporation - NovaLead Pharma Pvt. Ltd. - AmVac AG - KAEL-GemVax Co., Ltd. - Ausio Pharmaceuticals, LLC - Hanmi Pharmaceuticals, Co. Ltd. - SOM Biotech SL - Curadis GmbH - Balonco GMBH Drug Profiles - tadalafil - NX-1207 - topsalysin - MCS-2 - ozarelix - teverelix - AUS-131 - udenafil - AMV-110 - ASP-4901 - AMV-100 - ASP-0306 - ASP-6432 - CKD-902 - ADX-68692 - Sperol - tertomotide - ASC-JM.X2 - VLDM-01 - ESN-364 - SL-052 - Estrogen Receptor Program - S-40542 - NCE-403 - SOM-2391 - (tamsulosin dutasteride) - CH-5036249 - L1AD3 - Kisspeptin Peptide Antagonists - CR-1493 - SOM-2393 - Small Molecule to Inhibit Steroidal 5-Alpha Reductase for Benign Prostatic Hyperplasia - INT-0031 For more information visit http://www.researchandmarkets.com/research/f3..._prostatic
Chugai Pharma USA Announces Appointment of Chief Medical Officer
PR Newswire - Fri Apr 25, 1:00AM CDT
Chugai Pharma USA, LLC (CPUSA), Berkeley Heights, NJ a wholly owned subsidiary of Chugai Pharmaceutical Co., Ltd. (Chugai) Tokyo, Japan, member of the Roche Group, appoints Athos Gianella-Borradori, M.D. as Chief Medical Officer of CPUSA.
Former Roche Pharmaceuticals CEO Joins Mesoblast Board of Directors
GlobeNewswire - Wed Mar 05, 6:24PM CST
Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced that William M. Burns, former Chief Executive Officer of Roche Pharmaceuticals, has been appointed a non-executive Director of the Mesoblast Board, effective immediately.
Global 3D Flat Panel TV Market 2014-2018: Several Videogame Makers Investing Heavily in Making 3D Video Games
M2 - Thu Feb 13, 6:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/bjrqxw/global_3d_flat) has announced the addition of the "Global 3D Flat Panel TV Market 2014-2018" report to their offering. The analysts forecast the Global 3D Flat Panel TV market to grow at a CAGR of 15.4 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increase in 3D content broadcasts. The Global 3D Flat Panel TV market has also been witnessing the emergence of 4K resolution technology. However, the health risk associated with 3D technology could pose a challenge to the growth of this market. Key vendors dominating this space are LG Electronics Inc., Samsung Electronics Co. Ltd., and Sony Corp. Other vendors mentioned in the report are Panasonic Corp., Koninklijke Philips N.V., Sharp Corp., and Toshiba Corp. Commenting on the report, an analyst from the team said: The increasing popularity of 3D gaming among consumers is driving the Global 3D Flat Panel TV market. 3D gaming is an immersive experience that provides a real world experience to its users. Several videogame makers such as Sony Computer Entertainment Inc., Nintendo Co. Ltd., Electronic Arts Inc., Capcom Co. Ltd., Take-Two Interactive Software Inc., and Warner Bros. Interactive Entertainment Inc. are investing heavily in making 3D video games. This increasing popularity of 3D games has encouraged the vendors to manufacture and upgrade 3D TVs to support 3D gaming. According to the report, 3D technology is being used in the Entertainment sector such as 3D films, video games, gaming consoles, and 3D TVs. Blockbuster movies like Avatar not only increased the public awareness of 3D media but also increased the popularity of 3D films across the world. For more information visit http://www.researchandmarkets.com/research/bj...al_3d_flat About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Research Report: Hyperuricemia - Pipeline Review, H2 2013
M2 - Thu Dec 12, 2:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/3dtg38/hyperuricemia) has announced the addition of the "Hyperuricemia - Pipeline Review, H2 2013" report to their offering. 'Hyperuricemia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hyperuricemia, complete with latest updates, and special features on late-stage and discontinued projects. Scope - A snapshot of the global therapeutic scenario for Hyperuricemia. - A review of the Hyperuricemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hyperuricemia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Hyperuricemia. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Hyperuricemia pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned AstraZeneca PLC Teijin Pharma Limited Chugai Pharmaceutical Co. Ltd Kissei Pharmaceutical Co., Ltd. Nippon Chemiphar Co., Ltd. Polaris Group For more information visit http://www.researchandmarkets.com/research/3d...eruricemia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Helsinn and Chugai Pharma Marketing Enter into Agreement for Rights of Anamorelin, Currently in Development for Treatment of Anorexia-Cachexia Syndrome Related to Non-small Cell Lung Cancer in top EU Markets
PR Newswire - Mon Nov 11, 9:00PM CST
Swiss Pharma Group Helsinn seals an alliance with Japanese company Chugai by granting exclusive distribution & licensing rights to commercialize its innovative phase III ghrelin receptor agonist in Germany, France, Benelux, UK and Ireland
Hemophilia - Pipeline Review, H2 2013
M2 - Tue Sep 10, 3:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rvbm6c/hemophilia) has announced the addition of the "Hemophilia - Pipeline Review, H2 2013" report to their offering. 'Hemophilia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hemophilia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hemophilia. Scope - A snapshot of the global therapeutic scenario for Hemophilia. - A review of the Hemophilia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hemophilia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Baxter International Inc. Biogen Idec Inc. AstraZeneca PLC Nektar Therapeutics Cangene Corporation Lentigen Corporation Sangamo BioSciences, Inc. Pharming Group N.V. Novo Nordisk A/S BioMarin Pharmaceutical Inc. Chugai Pharmaceutical Co. Ltd Dong-A Pharmaceutical Co., Ltd. GTC Biotherapeutics, Inc. Octapharma AG Pain Therapeutics, Inc. Pfizer Inc. Bayer AG Living Cell Technologies Limited PROLOR Biotech, Inc. ReGenX Biosciences, LLC Alnylam Pharmaceuticals, Inc CSL Limited and many more... For more information visit http://www.researchandmarkets.com/research/rvbm6c/hemophilia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Kidney Disease - Pipeline Review, H2 2013
M2 - Thu Sep 05, 8:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zv6w3f/kidney_disease) has announced the addition of the "Kidney Disease - Pipeline Review, H2 2013" report to their offering. 'Kidney Disease - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Kidney Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Kidney Disease. Scope - A snapshot of the global therapeutic scenario for Kidney Disease. - A review of the Kidney Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Kidney Disease pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Genzyme Corporation Baxter International Inc. AstraZeneca PLC Eli Lilly and Company Quark Pharmaceuticals, Inc. Merck & Co., Inc. BioLineRx, Ltd. FibroGen, Inc. Novartis AG Chugai Pharmaceutical Co. Ltd Kureha Corporation LEO Pharma A/S Pfizer Inc. Zydus Cadila Healthcare Limited Hadasit Medical Research Services & Development Ltd NephroGenex, Inc. Cyclacel Pharmaceuticals Inc. OPKO Health, Inc. Evotec Aktiengesellschaft GENTIUM S.p.A. Celldex Therapeutics, Inc. Osteologix, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/zv...ey_disease About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Osteoarthritis - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nkkfb7/osteoarthritis) has announced the addition of the "Osteoarthritis - Pipeline Review, H2 2013" report to their offering. 'Osteoarthritis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Osteoarthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Osteoarthritis. Scope - A snapshot of the global therapeutic scenario for Osteoarthritis. - A review of the Osteoarthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Osteoarthritis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Johnson & Johnson Osiris Therapeutics, Inc. Seikagaku Corporation Sanofi-Aventis Ablynx TiGenix NV Novartis AG Astellas Pharma Inc. Chong Kun Dang Pharmaceutical Chugai Pharmaceutical Co. Ltd Pfizer Inc. Menarini Group Merck KGaA Bone Medical Limited Addex Pharmaceuticals Can-Fite BioPharma Ltd. Medivir AB Mesoblast Ltd Calzada Limited NicOx SA and many more... For more information visit http://www.researchandmarkets.com/research/nk...oarthritis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Eczema - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7twqxc/eczema_pipeline) has announced the addition of the "Eczema - Pipeline Review, H2 2013" report to their offering. 'Eczema - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Eczema, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Eczema. Scope - A snapshot of the global therapeutic scenario for Eczema. - A review of the Eczema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Eczema pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company GlaxoSmithKline plc Daiichi Sankyo Company, Ltd Merck & Co., Inc. Taisho Pharmaceutical Co., Ltd. Novartis AG Chugai Pharmaceutical Co. Ltd Dr. Reddy's Laboratories Limited Eisai Co., Ltd. Galderma S.A. LEO Pharma A/S Mitsubishi Tanabe Pharma Corporation Nippon Shinyaku Co., Ltd. Sun Pharmaceutical Industries Limited Sandoz Inc. Bayer AG AlbireoPharma Almirall, S.A. NicOx SA Regeneron Pharmaceuticals, Inc. Array BioPharma Inc. ProMetic Life Sciences Inc. and many more... For more information visit http://www.researchandmarkets.com/research/7t...a_pipeline About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Hepatitis C - Pipeline Review, H2 2013
M2 - Mon Sep 02, 8:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wq4dm8/hepatitis_c) has announced the addition of the "Hepatitis C - Pipeline Review, H2 2013" report to their offering. 'Hepatitis C - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hepatitis C, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatitis C. Scope - A snapshot of the global therapeutic scenario for Hepatitis C. - A review of the Hepatitis C products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hepatitis C pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Johnson & Johnson Boehringer Ingelheim GmbH F. Hoffmann-La Roche Ltd. United Therapeutics Corporation Medgenics Inc. Valeant Pharmaceuticals International GlaxoSmithKline plc Tekmira Pharmaceuticals Corp. Inovio Biomedical Corporation Idenix Pharmaceuticals, Inc. Gilead Sciences, Inc. Biotest AG Merck & Co., Inc. Lentigen Corporation BioLineRx, Ltd. Biotron Limited Novartis AG Isotechnika Pharma Inc. Achillion Pharmaceuticals, Inc. Chugai Pharmaceutical Co. Ltd and many more.... For more information visit http://www.researchandmarkets.com/research/wq...epatitis_c About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Research and Markets: Medical Chemicals (Global) Companies 2013 - Individual Assessment of the Top 100 Companies Featuring Chugai, Astra Zeneca and Boirin
Business Wire - Fri Jul 26, 11:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6qxgsf/medical_chemicals) has announced the addition of the "Medical Chemicals (Global)" report to their offering.
Medical Chemicals (Global) Companies 2013 - Individual Assessment of the Top 100 Companies Featuring Chugai, Astra Zeneca and Boirin
M2 - Fri Jul 26, 9:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8wzmsj/medical_chemicals) has announced the addition of the "Medical Chemicals (Global)" report to their offering. Plimsoll Publishing's Medical Chemicals (Global) Analysis provides a detailed overview of the Medical Chemicals (Global) market and delivers a comprehensive individual analysis on the top 100 companies, including CHUGAI PHARMACEUTICAL CO., LTD., ASTRAZENECA PTY LIMITED and BOIRON SA. This report includes a wealth of information on the financial trends over the past four years. Plimsoll Publishing's latest Medical Chemicals (Global) analysis is ideal for anyone wanting to: - See the market leaders - Identify companies heading for failure - Seek out the most attractive acquisition - Analyse industry trends - Benchmark their own financial performance Using Plimsoll's exclusive methodology, a quick glance of this Medical Chemicals (Global) report will tell you that 6 companies have a declining Plimsoll financial rating, while 15 have shown good sales growth. Each of the largest 100 companies is meticulously scrutinised in a one-page individual assessment and is analysed using the most up-to-date and current financial data. Every business is examined on the following features: - The Plimsoll Chart: A graphical assessment of a company's financial performance - An independent financial valuation - Four year assessment of the profit/loss and balance sheet - A written summary highlighting key performance issues Subsequently, you will receive a thorough market analysis highlighting the latest changes in the Medical Chemicals (Global) market. This section includes: - Best Trading Partners - Sales Growth Analysis - Profit Analysis - Market Size - Rankings For more information visit http://www.researchandmarkets.com/research/8w..._chemicals
Analysis of Nippon Kayaku 2013
M2 - Wed Apr 17, 4:11AM CDT
Research and Markets has announced the addition of the "Analysis of Nippon Kayaku" company profile to their offering. Aruvian Research presents Analysis of Nippon Kayaku. A complete and comprehensive analysis of Nippon Kayaku includes an overview of the industry the company operates in and then moves on to analyzing the company itself. Nippon Kayaku Co. Ltd. is a diversified chemical producer. The Company manufactures pharmaceuticals, dyestuffs, agrochemicals, explosives and synthetic resins. The Company also produces airbag inflators. It's product line include epoxy resins, UV-curing type resins, optical functional films, colors for inkjet printers, catalysts, pharmaceuticals, pharmaceutical API and intermediates, diagnostics, airbag inflators, micro gas generators for seatbelt pretensioners, squibs, agrochemicals and dyes, among others. The company also offers real estate leasing and contract manufacturing to pharmaceutical companies. Nippon Kayaku conducts its business through four reportable segments
Analysis of Chugai Pharmaceutical - In-depth Company Analysis 2013
M2 - Tue Apr 16, 9:53AM CDT
Research and Markets has announced the addition of the "Analysis of Chugai Pharmaceutical" company profile to their offering. Aruvian Research presents Analysis of Chugai Pharmaceutical. A complete and comprehensive analysis of Chugai Pharmaceutical includes an overview of the industry the company operates in and then moves on to analyzing the company itself. Chugai Pharmaceutical Co. Ltd. is a Japan-based pharmaceutical company. The Company operates in two business segments. The Domestic segment is engaged in the sale of pharmaceutical products manufactured by the Company through its nationwide appointed stores. This segment is also involved in the research, development, transportation and storage of pharmaceutical products, as well as the provision of literature research services for pharmaceutical information. The Overseas segment is engaged in the sale of its pharmaceutical products in overseas markets, such as Germany, the United Kingdom, France, Taiwan, China Mainland, Korea and the United States. T
Chugai and Debiopharm Group Announce an Exclusive License Agreement for Anti-Cancer Agent, FF284 (Debio 1347)
PR Newswire - Tue Jan 08, 12:00AM CST
Chugai Pharmaceutical Co., Ltd. ("Chugai"
and Debiopharm GroupTM ("Debiopharm" announced today that on December 17, 2012, they entered into a licensing agreement regarding FF284 (called Debio 1347 by Debiopharm) discovered by Chugai and which is about to start clinical development in oncology. 
